source
- Neoadjuvant T-DXd then THP cuts residual cancer burden vs standard chemo in high-risk HER2-positive breast cancerThe DESTINY‑Breast11 trial compared three neoadjuvant approaches for patients with high‑risk HER2‑positive early‑stage breast cancer: T‑DxD followed by paclitaxel, trastuzumab and pertuzumab (THP),…
- Trump executive order accelerates psychedelic drug development with priority review vouchers, funding and expanded right-to-tryPresident Trump signed an executive order that aims to speed the development and approval of psychedelic medicines. The order directs the FDA to issue priority review vouchers, expands right-to-tr…STAT · 4mo agoRegulatoryPositive